1Q10 EARNINGS RELEASE

DASA ON
(Bovespa: DASA3)
Last Price
(05/13/10)
R$ 15.33

Average Daily Traded:
R$ 11 MM in 1Q10

Market Capitalization:
R$ 3,520 billion
US$ 1.989 billion

Free Float: 99.9%

Conference Calls:

Portuguese
Data: 05/14/10
Time: 08:30 am (BRT)
Phone: 11 2101-4848
Code: DASA

English
Data: 05/14/10
Time: 11:00 am (BRT)
Phone: 1(973)935 8893
Code: 74171213

Felipe Rodrigues
IR Officer

ir@dasa.com.br

Phone: (011) 4197-6233
Fax: (011) 4197-5516

www.dasa3.com.br

DASA reached Ebitda margin of 26.1% and Gross Revenue of R$ 390.3 million this quarter.

OPERATIONAL AND FINANCIAL HIGHLIGHTS

- ✓ We have reached R$390.3 million Gross Revenue in the quarter, with an increase in all business segments resulting in 10.4% growth when compared to 1Q09.

- ✓ The highlight is still the Lab-to-lab segment showing 32.0% growth. In this quarter, Alvaro laboratory added 156 new labs to its portfolio of clients, having increased in the Southeast and North regions.

- ✓ The Public sector increased 21.7%, totaling R$47.2 million in revenue in this quarter. Besides the strong demand of the existing contracts, we have added new clients (Vila Velha and interior of Rio de Janeiro State).

- ✓ The Outpatient & Inpatient segment increased 6.5%, being affected by a larger volume of rain in the first quarter in the metropolitan region of São Paulo. Anyway, we have increased our average value per requisition in 6.6% year-on-year.

- ✓ The gross margin had an expressive improvement of 3.9pp, as a result of our focus on the portfolio management of PSCs and products, on the migration of clinical analysis production, on the price dealings with the payers and also on the dealings with the suppliers.

- ✓ EBITDA obtained 22.4% growth, reaching R$93.6 million and 26.1% margin in the year, representing an expansion of 2.6 pp YoY.

- ✓ During the first quarter, the investments in CAPEX totaled R$ 23.0 million. The investments were directed to: (i) refurbishing and expansion of the existing PSCs, (ii) purchasing of imaging equipment and (iii) implementation and development of production and front-end systems.

- ✓ We have finished 1Q10 with a comfortable cash position of R$232.4 million. The company is capitalized and prepared to continue growing through the acquisition of new brands as well as through expansion of the existing brands.

***Barueri, May 13, 2010**: Diagnósticos da América S.A. - DASA (BOVESPA: DASA3) has announced today the results referent to the first quarter of 2010r. The company´s operational and financial information are calculated on a consolidated basis and in million of Reais, based on accounting practices extracted from the Brazilian Corporate Law, except where stated otherwise. The information herein refers to the Company´s performance in the first quarter 2010, compared to the first quarter of 2009, except where stated otherwise.*

FINANCIAL HIGHLIGHTS

GROSS REVENUE

We have closed 2010 first quarter with a 10.4% growth year-on-year, thanks to our revenues diversification model, which once more has proved its success. Despite having a difficult comparison basis related to the first quarter of the previous year and an overwhelming intensity of rain in the metropolitan region of São Paulo in January and early February, the company reached a Gross Revenue of R$390.3 million.

The highlight of the quarter is once again the Lab-to-lab segment, which has increased 32% when compared to 1Q09. With the strong growth observed in the last 18 months, this segment already represents 10.6% of the total. The public sector has also shown excellent figures, increasing 21.7% when compared to the same period of last year, pushing its participation up to 12.1% of the revenue. The Outpatient & Inpatient segment, affected by a volume lower in the first month of the year, increased 6.5% compared to the same period of last year, generating R$ 301.9 million in the quarter.

The Same Unit sales revenue has increased 6.5% compared to 1Q09.



As previously commented, we continue driving our efforts towards the PSC´s optimization. We ended the quarter with 308 PSCs. We are planning the opening of four Standard PSCs, in the first semester of 2010. In the Lab-to-lab segment, we continue adding new clients, reaching 3,799 clients and in the public sector we closed the quarter with 757 collecting points.

The growth of the Public and Lab-to-lab sector in the last 12 months led the shares of these segments to grow 1.1 pp and 1.8 pp, respectively. The Private Hospitals sector has also continued growing its share in relation to other segments, reaching 9.7% of the total. The 0.5pp decrease observed in the Private segment must not be seen as a tendency, but a seasonality due to the rain that has affected the whole outpatient segment in the quarter. Anyway, we shall continue observing a dilution in the insurance and group medicine, due to the steeper increase of other payers.





Others: includes Clinical Trials, Occupational Health and OGM.

Private Sector

▪ Outpatient and Inpatient Market

The Outpatient & Inpatient segment has reached a revenue of R$301.9 million in the quarter, representing 6.5% growth against 1Q09. The volume of requisitions was affected, mainly in January and early February, by the large volume of rain in the metropolitan region of São Paulo. In March, we have already observed a recovery in the segment. We understand that this was an unusual volume for the quarter and it does not represent a tendency for the next quarters.



In this quarter, we have continued with our PSCs optimization program, which resulted in the closing of 13 PSCs. However, by observing the result of the closings in 3Q09, we can see that we are capturing at least 70% of the income from PSCs in the neighborhood.

In the imaging services line, we have reached R$135.2 million in revenue, representing a 7.7% year-on-year growth, reaching 44.8% of the Outpatient & Inpatient mix.

This growth is a result of three DASA projects: (i) maturity of last years investments in new PSCs (ii) a result of our strategy to increase the use of assets, mainly the imaging equipment at the PSCs, through active actions from the Call Centers which minimize the patients´ “no-show” and (iii) the optimization of the mix of services offered in the PSCs.

In the line of service of clinical analysis, we have reached revenues of R$ 166.7 million, representing a growth of 5.6% over the same period in last year.

We have reached 2.5 million of requisitions in 1Q10, a small growth compared to 1Q09. However, the average value of the requisitions has improved, showing a 6.7% growth when compared to the first quarter of last year. This improvement is due to a stronger mix in imaging services, but also to our efforts in price dealings with the payers.



Concerning the performance per segment, the revenue of standard brands has obtained a 10.0% increase, enlarging its share in 1.2 p.p. when compared to 1Q09. This growth is explained by a larger access to the diagnostic services by the low-income population, by the addition of new brands in the last quarters and, also, by the expansion of revenue and volume of the Popular Laboratory. This project, currently installed in 126 of the PSCs of the segment, aims to reach patients that do not have healthcare plan, by offering tests at popular prices. The income of this project has reached R$14.2 million in the 1Q10. The Premium and Executive segment brands have shown an increase of 4.6% compared to 1Q09.

Revenue per Brand Segmentation (R$ million)



▪ Lab-to-lab Market

Alvaro showed gross revenues of R$ 41.3 million in the quarter, representing a 32.0% growth when compared to 1Q09. This good performance reflects the increase of 17.5% in the number of laboratories served and a growth of the average revenue per lab of 12.4% compared to 1Q09. The number of requisitions per laboratory increased 12.9% reflecting a larger offer of tests per lab and the expansion of the geographical coverage that contributes to the increase in the number of client laboratories.

Gross Operating Revenue - Alvaro (R$ million)



Evolution of the # of Laboratories and Revenue per Requisition - Alvaro



In this quarter, Alvaro added 156 laboratories to its portfolio, totalizing 566 new laboratories since 1Q09. We have widened our presence in all regions of the Country, highlighting the Southeast and the North, which together added more than 200 clients in the year. This trend is a result of the diversification strategy of its portfolio and a larger demand of tests from small and medium laboratories.

	1Q09	2Q09	3Q09	4Q09	1Q10	1Q09 vs. 1Q10 Chg.%
Revenue (in R$ million)	31.2	34.9	38.2	39.0	41.3	32.0%
# of laboratories	3,233	3,382	3,537	3,643	3,799	17.5%
Average Revenue/laboratory (in R$ thousand)	9,665	10,332	10,808	10,716	10,860	12.4%
# Requisitions/laboratory	589	617	642	572	586	-0.4%
Average revenue/requisition (in R$)	16.4	16.8	16.8	18.7	18.5	12.9%

The South region continues with the largest shares in business in the Lab-to-lab segment with 35.4%, but there is a trend of dilution in its total share with our efforts in business in the Southeast, North and Northeast.



- **Public Sector**

CientíficaLab Revenue (R$ million)



In 1Q10, we have reached R$47.2 million revenue at CientificaLab, a brand that has its action exclusively in the public sector. This result represented 21.7% growth compared to the same quarter in last year.

It is due to the increase in volume observed in the existing contracts and also to the addition of new contracts in *Vila Velha* and in the interior of *Rio de Janeiro* State. We are observing a growing demand for third party imaging services in the public sector, which has been helping our mix and showing some interesting opportunities in new contracts, in this year.

We ended the quarter with 41 clients, which have demanded 1.41 million requisitions. Current clients totaled 757 collection points, which are demanding a growing volume of tests.

	1Q09	2Q09	3Q09	4Q09	1Q10	1Q10 vs. 1Q09 Var.%
Revenue (in R$ milions)	38.8	42.0	47.4	43.4	47.2	21.7%
# of Clients	43	48	43	37	41	-4.7%
# of Units Attended - Inpatient	79	86	88	80	84	6.3%
# of Units Attended - Outpatient	628	682	708	665	673	7.2%
# of Requisitions (in R$ Th.)	1,270	1,283	1,390	1,419	1,407	10.8%

Taxes on Services

In 1Q10, taxes on services accounted for R$ 23.3 million, representing 6.0% of gross revenues, aligned with the taxes booked in 1Q10 of 6.0% (R$ 21.1 million).

Discounts and Deductions

Discounts reached R$ 7.6 million, representing 1.95% of the gross revenue, versus 2.0% of 1Q09 (R$7.0 million). This 0.5 pp improvement is a consequence of maintaining the company policy of diversifying payers that do not have deduction policies.

Net Operating Revenue

Net operating revenue totaled R$ 359.4 million, representing 10.5% increase over the R$ 325.4 million in 1Q09, remaining in line with the growth of the gross revenue (10.4%).

Cost of Services

The cost of services includes expenses related to the operation of the PSCs, cost of clinical analysis and imaging test production.

PSCs costs are divided into fixed - personnel, general and public services, rents and facility maintenance; and variable - materials used in the collection and production of clinical tests and imaging diagnostics, which may vary according to the volume of requisitions processed. Costs related to the processing of clinical tests include reagents, personnel and the operating costs of the central laboratories. Diagnostic imaging processing costs include expenditures with equipment maintenance, expenses with test report centers and the hiring of specialized medical clinics to issue reports on these tests.

The variations on the line of personnel, materials, services and utilities and general expenditures are due to the evolution of each segment and the difference between their costs structure. The main difference is in the attendance, where the B2C segment has collection units and all costs related to this operation, showing its main costs as personnel and services and utilities. At the B2B segment its main cost is material, as it does not have collection unit, but only the processing of tests.

In this quarter, the costs of services totalized R$ 209.5 million or 58.3% of the net revenue. This percentage represents 3.9 p.p. dilution when compared to the 1Q09 costs.

Cost of Services - 1Q10 versus 1Q09

	In R$ Million		*% of Net Revenues*		*1Q10 vs 1Q09*	
	1Q10	1T09	1Q10	1T09	Δ %	Dillution (p.p)
Personnel	63.1	66.3	17.6%	20.4%	-4.8%	-2.8
Materials	61.5	61.6	17.1%	18.9%	-0.2%	-1.8
Services and Utilities	82.7	72.4	23.0%	22.2%	14.3%	0.8
General	2.2	2.2	0.6%	0.7%	-2.1%	-0.08
Cost of Services Rendered	**209.5**	**202.5**	**58.3%**	**62.2%**	**3.5%**	**-3.9**

Source: DASA

Below are the variations in the main lines of costs of services as a percentage of net revenue versus the same period of last year:

Cash Operating Expenses Breakdown - 1Q10 versus 1Q09



1) We have obtained a significant reduction in personnel line. During the last months we have adjusted our headcount as a result of the benchmarking being run among the outpatient units, the commercial support units and also in the production area, with the consolidation of the Clinical Analysis specialties. Although hires were made in large expansion areas (such as CientíficaLab operation in Rio de Janeiro), the net result was a 2.8 pp dilution in this line.

2) Costs of materials showed 1.8pp dilution, mainly due to our efforts on price and delivery time dealings with several suppliers. This line is also

affected by the consolidation occurring in Clinical Analysis production, leading to a more rational utilization of reagent kits.

3) Services and utilities line has increased 0.8pp when compared to the previous year. In this line, costs of PSCs occupation, medical service for the elaboration of imaging reports and initial costs for production migration are booked. The advance of imaging services in the mix has a negative impact on the costs of services and utilities.

4) General expenses line has decreased 0.08 p.p in its participation on net revenue when compared to 1Q09. This line accounts for costs with general fees, insurances and representation expenses.

Cash Gross Profit

In this quarter, the cash gross profit totaled R$ 149.9 million, an increase of 22.0% over 1Q10, and the gross margin of the period reached 41.7%.

Cash Operating Expenses

In 1Q10, operating expenses totaled R$ 56.3 million, representing a concentration of 1.4 p.p. over 1Q09, mainly due to a concentration of profit sharing expenses booked this quarter.

Cash Operating Expenses Breakdown- 1Q10 versus 1Q09

	In R$ Million		*% of Net Revenues*		*1Q10 vs 1Q09*	
	1Q10	**1Q09**	**1Q10**	**1Q09**	**Δ %**	**Dillution (p.p)**
General and Administrative	(48.1)	(44.5)	13.4%	13.7%	8.1%	-0.3
Profit Sharing Program	(8.4)	(2.9)	2.3%	0.9%	188.4%	1.4
Other Operating Revenues/Expenses	0.2	1.1	-0.1%	-0.3%	-76.5%	0.3
Cash Operating Expenses	**(56.3)**	**(46.4)**	**15.7%**	**14.3%**	**21.3%**	**1.4**

Source: DASA

The main year-on-year variations in cash operating expenses as a percentage of net revenue are described below:

1) General & Administrative expenses (G&A) have reached R$48.1 million in 1Q10, representing a dilution of 0.3 p.p. This is mainly a result of the use internalization of maintenance labor in 1Q10 and the Call Center expansion that occurred last year. It is important to highlight that in 1Q09 the current PDD policy had not been implemented yet.

2) In the line of PPLR – Profit Sharing Program – in 1Q10, R$ 8.4 million were accounted as a provision for the distribution of profits among the employees of the company compared to R$2.9 million of the previous year;

3) In the quarter, R$ 0.2 million were booked under other operating revenues, related to the recovery of sundry expenses and provision reversion.

Adjustment for Bad Debt Provision (PDD)

DASA closed the 1Q10 with a requirement of R$1.6 million additional PDD in accordance with the current policy. This reduction in relation to the last quarters is already a result of the revision of administrative process of receivables and risk.

EBITDA

In 1Q10, EBITDA totaled R$ 93.6 million, versus R$ 76.5 in 1Q09, with a margin of 26.1% moving up by 22.4%.

EBITDA (R$ million)



	2004	2005	2006	2007	2008	2009	1Q09	1Q10
EBITDA margin	17.9%	21.9%	19.5%	19.2%	21.7%	23.0%	23.5%	26.1%

Source: DASA

Depreciation and Amortization

The costs and expenses with depreciation and amortization totaled R$ 26.9 million, or 7.5% of net revenue, versus R$ 25.7 million (7.9% of the net revenue). It is important to mention that we still benefit from the effect of tax credit on amortization premium.

Net Financial Expenses

In relation to the same period of last year, the net financial expenses had an increase due to Mark-to-market of hedge position in International Notes coupons and also for not benefiting from the Real variation in face of the dollar. In this quarter, net financial expenses accounted for R$16.3 million versus R$6.1 million in 1Q09.

	1Q09	1Q10
Net Financial Expenses	**6.1**	**16.3**
Exchange Rate Fluctuation - Lease/Financing	**(1.4)**	**3.1**
International Notes	**(10.5)**	**(0.1)**
Interest Expenses	11.3	9.9
Financial Revenue	(0.1)	(10.0)
Revenue/Financial Expenses	-	-
Hedge Result (swap)[1]	(21.7)	(0.0)
Debentures	**6.3**	**2.9**
Others[2]	**11.8**	**10.5**

1 - Includes Mark-to-market of derivatives
2 – Interest in equipment leases in local currency, working capital loans and guaranteed account.

Exchange Rate Fluctuation - Lease / Financing: Refers to the updating of indebtedness in dollars, which, during the quarter, did not have hedge. These expenses do not represent disbursement at the first moment, as more than 94% of the debts that resulted in this variation are long term debt.

International Notes: In May 2008, DASA issued 10 year International Notes in the amount of US$ 250 million. The issuing aimed to capture funds to finance the expansion of DASA´s activities.

Hedge (Swap): refers to the revenues and expenses derived from to the financial instruments, including the mark-to-market of these derivatives. As the Company has revenues denominated in Reais, these instruments are used for the protection against currency changes, mainly, on the first five years of the interest payments of the international notes. We point out that in April 2010 a hedge of all exchange exposition on the indebtedness was made. Furthermore, DASA does not have any derivative or other speculative risky assets or liabilities.

Income Tax and Social Security Contribution

The Income Tax and Social Security Contribution showed a balance of R$ 17.2 million, in the quarter compared to R$ 10,6 million in 1Q09

Net Profit

In 1Q10, the net profit totaled R$33.3 million compared to R$33.8 million in 1Q09, mainly as a result of higher financial expenses.

INDEBTEDNESS

DASA net debt totaled R$ 453.4 million in 1Q10. Around 77.8% of DASA´s total gross indebtedness is long term and around 69.0% are denominated in foreign currency. Most of the debt in foreign currency refers to our International Notes, but are also related to equipment financing. The debt in local currency comes largely from debentures.

Net Indebtedness Breakdown

R$ MM	1Q10	%	1Q09	%
Short Term	**(166.7)**	**22.2%**	**(223.0)**	**21.7%**
Domestic Currency	137.6		182.2	
Foreing Currency	29.1		40.8	
Long Term	**(582.6)**	**77.8%**	**(806.3)**	**78.3%**
Domestic Currency	94.6		199.1	
Foreing Currency	488.0		607.2	
Total ST + LT	**(749.3)**	**100.0%**	**(1,029.3)**	**100.0%**
Cash and Cash Equivalents	232.4		395.4	
Domestic Currency	38.4		22.5	
Foreing Domestic	194.0		372.9	
(+) Escrow	63.5		61.2	
Net Debt	**(453.4)**		**(572.7)**	

Obs.: local Currency (Short and long Term) – includes escrow deposits in a total amount of the R$ 61.2 million.

Source: DASA

INVESTMENTS

During the first quarter, the investments in CAPEX totaled R$ 23.0 million. The investments were directed to: (i) refurbishing and enlarging the existing PSCs, (ii) purchasing of imaging equipment and (iii) implantation and development of production and operation attendance system.

CAPEX (R$ million)	CAPEX 1Q10 Breakdown
	

Source: DASA

STOCK MARKET

DASA shares closed the quarter at R$ 15.60, accumulating an increase of 9.5% in this quarter, versus 2.6% increase of the Ibovespa. Between January and March 2010, DASA shares were transacted on 100% of Bovespa´s trading sessions, with a daily traded average of R$ 11.0 million.

Financial Highlights

	R$ million			Margin %	
	1Q10	*1Q09*	Margin %	*1Q10*	*1Q09*
Gross Revenues	**390.3**	**353.4**	**10.4%**	**108.6%**	**108.6%**
Net Revenues	359.4	325.4	10.5%	100.0%	100.0%
Cost of Services Rendered	(229.5)	(222.1)	3.3%	-63.8%	-68.3%
Gross Profit	129.9	103.3	25.8%	36.2%	31.7%
EBITDA	93.6	76.5	22.4%	26.1%	23.5%
Net Profit (Loss)	33.3	33.8	-1.4%	9.3%	10.4%
Net Margin (%)	***9.3%***	***10.4%***			
Shareholders' Equity	***572.5***	***512.7***	**11.7%**	**159.3%**	**157.6%**
Net Cash/Debt	(453.4)	(572.7)	-20.8%		
Source: DASA					

EBITDA AND NET PROFIT STATEMENTS

	1Q10	1Q09
R$ million	Total	Total
Gross Revenues	***390.3***	***353.4***
(-) Deductions	*(30.9)*	*(28.1)*
Net Revenues	**359.4**	**325.4**
(-) COGS Cash	(209.5)	(202.5)
Gross Profit Cash	***149.9***	***122.9***
(-) Expenses Cash	(56.3)	(46.4)
EBITDA	**93.6**	**76.5**
(-) Depreciation and Amortization (Goodwill)	(26.9)	(25.7)
(-) Financial	(16.3)	(6.1)
(-) Income Tax and Social Contribution	(17.2)	(10.6)
(-) Minority Shareholder	-	(0.3)
Net Income (Loss)	**33.3**	**33.8**

Demonstração de Resultado do Período

R$ million	1Q10	1Q09	Δ %
Gross Operating Revenues	***390.3***	***353.4***	***10.4%***
Deductions	*(30.9)*	*(28.1)*	10.2%
Sales Taxes	(23.3)	*(21.1)*	10.6%
Discounts	(7.6)	*(7.0)*	8.9%
Net Operating Revenues	***359.4***	***325.4***	***10.5%***
Cost of Services Rendered	(229.5)	*(222.1)*	3.3%
Gross Profit	***129.9***	***103.3***	***25.8%***
Operating Expenses	*(79.5)*	*(58.6)*	*35.6%*
Selling, General and Administrative Expenses	(65.6)	*(53.5)*	22.5%
Net Financial Expenses	(16.3)	*(6.1)*	165.8%
Goodwill Amortization	-	-	NA
Other Operating Expenses	2.4	*1.1*	132.2%
Net Loss Before Income Tax and Social Contributio	***50.5***	***44.7***	13.0%
Income Tax and Social Contribution	(17.2)	*(10.6)*	62.1%
Minoritary Shareholders	-	*(0.3)*	-100.0%
Net Income (Loss)	**33.3**	***33.8***	**-1.4%**

Consolidated Balance Sheet

ASSETS	1Q10	1Q09
CURRENT ASSETS	**730.0**	**846.2**
Cash and Cash Equivalents	31.1	12.6
Marketable Securities	210.0	382.8
Accounts Receivables	308.7	315.9
Inventories	46.5	37.8
Recoverable Taxes	48.2	53.8
Deferred Taxes	63.3	20.0
Advances to Suppliers	4.6	4.7
Prepaied Expenses	4.7	3.8
Financial Instruments	1.5	7.4
Other Receivables	11.5	7.5
LONG TERM ASSETS	**136.7**	**194.1**
Marketable Securities	54.8	61.2
Recoverable Taxes	-	-
Deferred Taxes	73.3	82.5
Judicial Deposits	8.5	6.2
Other Credits	0.0	44.1
Financial Instruments	-	0.0
Prepaied Expenses		0.0
PERMANENT	**742.7**	**803.7**
Investments	0.3	0.3
Property, Plant and Equipment	415.3	471.2
Intangible	327.1	332.2
Defferred Charges	-	-
TOTAL ASSETS	**1,609.4**	**1,844.0**

LIABILITIES	1Q10	1Q09
CURRENT LIABILITIES	**355.5**	**382.8**
Suppliers	50.0	52.7
Loans and Financing	67.0	143.4
Taxes and Contributions Payable	6.7	7.9
Deferred Taxes	4.1	1.4
Salaries, Social Charges and Vacation	57.2	53.5
Tax Payable	13.0	11.3
Tax in Installments	9.4	9.0
Accounts Payable from Acquisition of Subsidiaries	13.2	8.0
Debenture	66.5	66.5
Dividends	-	0.0
AdvanceS from Customers	-	0.2
Other Accounts Payable	68.5	28.9
LONG TERM LIABILITIES	**681.4**	**946.7**
Marketable Securities	498.0	670.2
Tax in Installments	14.0	15.2
Deferred Taxes	10.4	22.0
Provisions for Contingencies	93.9	102.8
Accounts Payable from Acquisition of Subsidiaries	60.9	70.0
Debenture	-	66.5
Other Accounts Payable	4.1	-
MINORITARY SHAREHOLDERS	**-**	**1.9**
SHAREHOLDER´S EQUITY	**572.5**	**512.7**
Capital	402.1	402.1
Capital Reserves	137.1	110.6
Accumulated Earnings	33.3	-
TOTAL LIABILITIES	**1,609.4**	**1,844.0**